Adjunctive Treatment with GLP-1 and Dual GLP-1/GIP Receptor Agonists for People with Type 1 Diabetes: Consensus Report and Practical Guidelines for Safe Use
Scope
As issued by the authors
Safe use of GLP-1 and dual GLP-1/GIP receptor agonists (RAs) as adjunctive therapy in T1D, for diabetes clinicians and people with T1D
Original publication
Adjunctive Treatment with GLP-1 and Dual GLP-1/GIP Receptor Agonists for People with Type 1 Diabetes: Consensus Report and Practical Guidelines for Safe Use. Diabetes Technol Ther. Published 5 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →